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Abstract
Background: Basal cell carcinoma is the commonest human cancer. Despite increasing incidence it remains poorly 
researched. While not life threatening it can cause significant cosmetic disfigurement. Imiquimod, a cream which 
enhances the body's immune response, may help deal with the number of cases that occur in low-risk sites, especially 
when good cosmetic results and home use without surgery are needed.
This study aims 1. To compare excisional surgery with imiquimod cream for nodular or superficial basal cell
carcinoma in low risk sites, with respect to 3 year clinical clearance, cost-effectiveness and cosmetic results. 2. To
ascertain if certain phenotypic features and gene polymorphisms predict tumour responsiveness to treatment.
Methods/Design: Five hundred participants with low risk nodular or superficial basal cell carcinoma will be recruited 
from hospitals to this multi-centre, randomised, parallel group, controlled phase III trial. Treatment in the imiquimod 
group is for 6 weeks for superficial basal cell carcinoma and 12 weeks for nodular basal cell carcinoma. Both treatment 
groups are followed up in clinic for 3 years. Primary outcome variable: the proportion of participants with clinical 
evidence of success (no recurrence) at 3 years. The primary outcome will be compared between the two treatment 
groups. Secondary outcomes include: i) clinical success at 1, 2 and 5 years, ii) time to first recurrence, iii) cosmetic 
appearance of lesion site after treatment, iv) level of pain, and v) cost-effectiveness. Safety and tolerability data will also 
be reported.
Discussion: This study protocol describes a pragmatic randomised controlled trial which it is hoped will address the 
above uncertainties. Three-year results will be available towards the end of 2010.
Trial registration: Meta-register: NCT00066872, Eudract No. 2004-004506-24, ISRCTN48755084.
Background
Basal cell carcinoma (BCC), or "rodent ulcer" is the com-
monest human cancer [1-3] affecting at least 30,000 UK
people annually, with increasing incidence [4], especially
in younger people [5] and in those with higher social class
[6]. Although not life threatening, BCC can cause signifi-
cant cosmetic disfigurement, and remains one of the
most poorly researched human cancers [7]. Most BCCs
are treated surgically in hospitals, but current treatment
provision is becoming saturated in many centres in the
UK. A systematic review highlighted topical imiquimod
as a potentially useful therapy for superficial basal cell
carcinoma and raised the possibility that it could also be
useful for dealing with the bulk of low risk nodular basal
cell carcinomas - thereby releasing limited surgical
resources in the UK dermatology centres to tackle more
complicated tumours at high risk sites.
Imiquimod cream enhances the body's immune
response. Although not as effective as surgery, it may
result in a better cosmetic result (potentially important as
a majority of BCCs appear on the face and neck [8,9])
together with the added convenience of home applica-
tion.
Prior to this study, imiquimod cream was not used rou-
tinely for BCC, and clinical opinion was divided regard-
ing its potential usefulness for different types of BCC. It is
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tion of practice without adequate evaluation.
If imiquimod 5% cream has an acceptable success rate,
is cost-effective and easy to use, then it could be an effec-
tive treatment option for the routine first treatment of the
majority of low risk nodular and superficial BCCs seen in
skin cancer clinics in the UK and elsewhere. Recurrences
and high risk BCCs could then be dealt with surgically by
dermatologists and plastic surgeons working as part of
the skin cancer teams. Treatment with imiquimod could
even start in the community after histological diagnosis,
using a strict protocol to prevent indiscriminate use (and
diagnostic uncertainty and/or possible delay in mela-
noma diagnosis) and hence increase in costs.
Methods/Design
Trial objectives
We seek to answer the following questions:
1. Can imiquimod 5% cream applied topically give an
acceptable and clinically useful success rate (3 year clini-
cal clearance) and acceptable side effect profile when
compared with excision surgery for superficial and nodu-
lar BCC at low risk sites?
2. Is imiquimod more cost effective than surgery for
low-risk BCC?
3. Does imiquimod result in a more aesthetically
acceptable result than conventional excision?
4. Do certain phenotypic features and gene polymor-
phisms predict tumour responsiveness to treatment?
We hypothesise that the clinical success rate at 3 years
among participants treated with imiquimod cream will
not be inferior to the clinical success rates obtained from
surgery.
Both nodular and superficial BCC are included in this
trial because in real life clinicians are unlikely to make an
a priori decision on what constitutes a nodular and
superficial lesion, and even if they do, their clinical deci-
sion may be wrong (compared to histology, which is also
somewhat arbitrary). The agreement between clinical
and histopathological diagnosis will be looked at.
Long-term follow-up is needed to catch late recur-
rences of slower-growing tumours [10-13]. There is a real
danger that lesions that appear clear in the short term e.g.
at 1 year, will recur in the long term. It is also unclear
whether the short-term histological clearance reported in
the Phase II studies can be translated into a durable clini-
cal clearance, and there may be a gradient of treatment
response depending on the histological subtype. More
precise estimates of treatment efficacy using much larger
sample sizes are needed for the commoner nodular BCC.
A definitive independent trial with cost-effectiveness data
and long term follow up will help to inform patients,
health care workers and the NHS. Information on possi-
ble predictors (clinical and genetic) of treatment response
might also be useful for guiding clinical practice.
Trial design
Prospective, multi-centre, randomised, parallel group,
controlled phase III trial, to compare excision surgery and
imiquimod cream for nodular and superficial basal cell
carcinoma presenting in low risk areas [3]. This is a sim-
ple pragmatic study [14].
The consultant dermatologist will decide if the lesion is
superficial or nodular at the study outset (confirmed by
the diagnostic biopsy result).
Trial interventions
1. Imiquimod 5% cream once daily for 6 (superficial -
clinically diagnosed) or 12 (nodular) weeks total, or
2. Surgical excision with a 4 mm margin (accepted stan-
dard at trial set-up). The surgical group will be operated
on as soon as local conditions permit.
Treatment failures (after either a biopsy or a period of
watchful waiting) will be treated by surgical excision.
Treatment duration and frequency of dosing are based on
results of existing studies [15] at study set-up, and a bal-
ance of efficacy with effort for the participants and possi-
ble side effects. The dosing frequency was unchanged
after the manufacturers presented results from a large
dose-finding clinical study to us, however after the start
of this study imiquimod became licensed for superficial
BCC, with a 5 days per week dosing frequency.
In order to identify possible genetic markers for tumour
response, 5 ml of blood will be taken from consenting
participants. Methods for analysing the genetic marker
data are given in a separate genetic markers addendum to
the protocol.
Treatment adherence
In the imiquimod group local reactions and the long
duration of daily treatment are factors which could com-
promise compliance. The application of the cream will be
explained. Cards for monitoring daily pain will be given
to participants in both groups, and returned every six
weeks. A telephone help-line will be available for answer-
ing day to day problems. Participants will be asked to
return used and unused imiquimod sachets (one per day
of treatment).
Participant selection
At each of 12 (initially three) hospitals potentially suitable
participants will be asked to speak to the research nurse,
who explains the study, checks eligibility and deals with
informed consent. Entry criteria are as broad and inclu-
sive as possible in order to approximate the sort of
patients encountered outside the usual strict clinical trial
environment and hence to improve external validity.
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• Men and women of any age who present clinically
with either primary nodular or superficial BCCs, or a
skin lesion other than BCC which turns out on histol-
ogy to be a superficial or nodular BCC
• Any number of BCCs (although only one per partic-
ipant is selected for the study)
• Histologically proven BCC (usually a punch or shave
biopsy specimen of no more than 25% of the total
lesion, though sometimes at surgery)
• Location of primary nodular/superficial BCC in low
risk areas (avoiding use of imiquimod in areas at high
risk of recurrence where delay of appropriate surgery
might result in more invasive procedures)
• Informed consent
• Must have access to a telephone
Exclusion criteria
• Genetic or nevoid conditions such as Gorlin's syn-
drome
• Morphoeic (microinfiltrative) trial lesion as diag-
nosed clinically (even if not histologically classed as
morphoeic - histological sample may have missed
infiltrative nature of lesion)
• Allergy to any of the interventions
• Involvement in a trial of another experimental inter-
vention
• Life threatening disease
• Bleeding disorders
• Not available for follow up for 3 yrs
• Pregnant, intention to become pregnant during
treatment phase of the trial, or breastfeeding
Outcome measures
Primary
The proportion of participants with clinical evidence of
"success" (defined as absence of treatment failure or any
signs of local recurrence) at 3 years as judged by a consul-
tant dermatologist, as would occur in routine clinical
practice. Participants allocated cream, that subsequently
require surgery for poor response or recurrence will be
counted as treatment failures, if histology is proven to be
positive.
Secondary
i) The proportion of participants with clinical success at
one, two and five years.
ii) Time to first recurrence (classified into one of the
following 5 categories according to the period between
follow up visits when this occurred: "prior to year 1 visit";
"between year 1 visit and year 2 visit"; "between year 2
visit and year 3 visit"; "between year 3 visit and year 5
visit"; "no recurrence prior to year 5 visit"). The actual
time of recurrence is not known, but only the visit at
which it is diagnosed.
iii) The proportion of participants with a lesion of
excellent or good appearance at 6 months and at 3 years.
(The cosmetic appearance of a participant's lesion will be
rated independently by the participant and blinded
observer. using a five point scale ("Excellent", "Good",
Fair", Poor", "Very poor")).
iv) The proportion of participants experiencing a mod-
erate or more severe level of pain a) during treatment and
b) in the 16 weeks following treatment. (This will be mea-
sured daily using a six-point scale ("No pain", "Mild",
"Mild-Moderate", "Moderate", "Moderate-Severe",
"Severe") using a questionnaire completed at home).
v) Cost effectiveness to include number of participant
visits to hospital, as well as cost of treatment per session.
Clinical clearance will not be routinely confirmed by
further biopsy mainly because a) this would not happen
in clinical practice and b) participants benefitting from an
excellent cosmetic result in the cream group are unlikely
to want a biopsy scar. If, however, the clinician is con-
cerned there is a recurrence, then he/she will biopsy that
lesion exactly as would happen in routine follow-up care
from other treatment modalities.
Adverse events will be collected from all participants
up to the 1 year visit, thereafter only events considered
serious or related to the trial comparators (imiquimod or
surgery) will be collected.
Health service research issues
An economic evaluation will include:
1. A cost-comparison analysis (net impact of all
resource changes) of the two treatment strategies.
2. A cost-effectiveness analysis presented in the form
cost per 'cleared participant'.
3. A valuation (in monetary terms using willingness to
pay) of the perceived benefits of both treatment strate-
gies, which (depending on results) could be incorporated
into a cost-benefit analysis.
Follow-up of outcome measures
The nurse will make a telephone call to the participant at
two weeks to discuss any early problems, followed by
clinic follow-up at 6, 12, and 18 weeks, 6 months, 1, 2 and
3 years. The dermatologist will also see the participant
briefly, at 12 weeks (surgery only), 18 weeks (superficial,
imiquimod only), 6 months (nodular, imiquimod only), 1,
2 and 3 years. A postal follow-up of documented recur-
rences at 5 years will be conducted by writing to GPs,
hospital clinics and obtaining pathology records. See fig-
ure 1.
Extra clinic visits can be arranged if participants are
concerned about adverse reactions or progress. Those
participants developing a brisk inflammatory response to
imiquimod to the extent that they find it difficult to con-
tinue can follow a pre-defined schedule of rest periods
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analysed with the main data with an appropriate sensitiv-
ity analysis.
Randomisation
One lesion per patient will be chosen for the study, so that
the unit of analysis will be patients rather than tumours.
For those patients with multiple suitable BCCs, the
research nurse will pick one before randomisation as
below:
• The one that the patient is most bothered about, or
first went to the doctor about
• If that does not apply, or the tumour in question
does not meet the criteria, then the one that is easiest
for the patient to reach.
• If this applies to more than one, the biggest will be
chosen.
• If the patient wants both nodular and superficial
BCCs treated, then a nodular BCC should be chosen
to ensure there is enough cream for all (i.e. 12 weeks
rather than six weeks of cream). If it happens that the
histology shows the chosen nodular lesion not to be a
BCC, but a superficial one is (assuming it had a
biopsy), then the patient should be withdrawn, and
re-randomised by the superficial BCC list.
Other current BCCs may be treated in the same way as
the randomised one if the patient wishes, but this option
should only be offered if needed, and BCCs are clinically
suitable.
The identified BCC will be biopsied (three centres
biopsy post randomisation, this being part of surgery for
the surgery group). Patients eligible for inclusion and for
whom consent has been obtained will be randomised to
topical imiquimod or surgery, according to a pre-pre-
pared randomisation schedule, generated by computer at
the Trent Research and Development Support Unit
(Trent RDSU). The allocation is obtained at the baseline
visit, using a central telephone randomisation service run
by independent staff at the Trent RDSU. This ensured
concealment of allocation.
Randomisation will be stratified according to lesion
type (nodular or superficial, defined clinically) and by
centre, thus minimising the differences in the most
important predictor baseline variables. There will be no
attempt to equalise numbers of nodular and superficial
BCCs randomised.
The participant's general practitioner and consultant
will be informed about the participant's involvement in
the study.
To minimise selection bias the allocation sequence will
be concealed from participants, healthcare staff and
investigators - the allocated treatment only being
obtained after the participant had decided to take part in
the trial (though the participant is always free to with-
draw from the study at any time). Masking of the two very
different interventions will not be possible for partici-
pants, and only partially possible for observers. We will
determine whether there is evidence of dermatologists'
observer bias at the 3 year visit by asking an independent
panel of 3 dermatologists to judge "clinical success" from
digital photographs.
The trial and full protocol are registered with the
Cochrane Skin Group Ongoing Trials Register [http://
Figure 1 SINS study design overview.
Screening  Baseline        Week 2     Week  6    Week 12     Week 18         6 months        year 1          year 2                 year 3      year 5 
                                                          20 endpoint   20 endpoint       10 endpoint        20 endpoint 
             Surgery         ‘phone            FU    FU            FU                  FU           FU         FU                      FU    LTS 
    FU                                                
  Cream            ‘phone           FU   FU            FU                   FU           FU                 FU                      FU    LTS  
               FU                                                 
* Week 12 early failure for surgery 
** Week 18 early failure for superficial BCC  
FU = follow up 
LTS = Long term surveillance of 
recurrences by writing to GPs, hospital 
clinics and pathology records.
*** Month 6 early failure for nodular BCC  
Ozolins et al. Trials 2010, 11:42
http://www.trialsjournal.com/content/11/1/42
Page 5 of 7www.nottingham.ac.uk/ongoingskintrials/ NB protocol
not accessible from Cochrane], and with the UK meta-
register of trials. Consumers with BCC have already been
and will continue to be involved in commenting on the
study design and conduct.
Sample size
Based on initial Phase II data, it is highly unlikely that
imiquimod cream will be superior to excisional surgery,
so this is essentially a non-inferiority study i.e. the imiqui-
mod success rate will be no worse than a pre-determined
lower acceptable level.
The original total sample size estimate was for 740 par-
ticipants, to be recruited over 18 months in three centres.
This assumed a 1-tailed significance with (alpha) = 1%,
power (1-β) = 80%, a 3 year success rate with surgery of
97% and for imiquimod of 90%, a lower 98% confidence
limit of 84%, and allowed for a 10% drop-out rate. An imi-
quimod success rate of 90% was generally considered the
lowest percentage to change dermatologists' practice,
assuming success rates approaching 90% for other com-
monly used treatment modalities such as cryotherapy or
curettage. The estimate is conservative, considering imi-
quimod as a direct competitor to surgery or other treat-
ments, as opposed to using the cream first and then
surgery if it fails i.e. sequential technology application.
Due to recruitment being slower than expected (many
BCCs in high risk areas and the trial was too time con-
suming for potential participants), nine more centres
were added and the recruitment period extended to 42
months; later (March 2006) the sample size was revisited.
Various scenarios were considered. For a sample size of
500 the lower confidence interval would be within less
than 10 percentage points of the actual imiquimod suc-
cess rate assuming imiquimod success rate is at least 70%
- probably acceptable precision for influencing practice.
The revised overall sample size of 500 is considered to be
both useful and achievable.
Statistical analysis
The primary efficacy analysis will be performed using
both a Full Analysis Set and the Per Protocol Set of par-
ticipants. All other efficacy analyses will use the Full
Analysis Set only. Data will be analysed using Stata ver-
sion 10.1. No adjustments will be made for multiple end-
points. There is only one primary outcome variable.
Secondary outcome variable findings and subgroup anal-
ysis findings will be interpreted with caution in view of
the number of statistical tests undertaken.
Participants in the three centres performing the biopsy
post-randomisation, and who were found not to have a
BCC, did not continue in the study; they will be excluded
from the analysis.
An independent Data and Safety Monitoring Commit-
tee reviewed data with the trial statistician relating to
severe skin reactions.
An early stopping rule was proposed to safeguard par-
ticipants with nodular BCC against unacceptably low
early clearance rates from imiquimod however, due to the
higher proportion of superficial BCCs than expected, all
participants were recruited before the planned number of
participants for the interim look were recruited, so the
assessment was not made.
Sub group analyses are to be performed only for the
primary outcome measure. These will assess whether the
effectiveness of imiquimod cream in comparison to sur-
gery is different in participants with:
• nodular lesions and those with superficial BCCs
(confirmatory analysis)
• trunk lesions and those with head lesions (explor-
atory analysis)
• lesions ≤15 mm diameter and those with lesions
greater than 15 mm diameter (exploratory analysis)
For each of the above analyses sensitivity analyses will
be performed including and excluding participants with
BCCs who are immunosuppressed at baseline.
Missing data:  sensitivity analyses assuming both worst
and best case scenarios will be performed for the primary
outcome measure. Potential outliers will be identified by
range checks and subjected to standard query generation
and resolution. In order to minimise loss of efficiency in
the analysis, the nine smallest centres will be pooled
together to form a composite centre.
Non inferiority margin: This is based on a 97% success
rate for surgery and a lower 98% confidence boundary of
84% for Imiquimod cream. This gives a non-inferiority
margin (lower boundary of a 98% confidence interval for
the relative difference expressed as a relative risk (imiqui-
mod relative to surgery)) of 0.87. This margin was deter-
mined by the clinical judgement of the 4 clinicians who
sit on the Trial Steering Committee. The non-inferiority
margin will only apply to the analysis of the primary out-
come for which non-inferiority is hypothesized.
Two-sided 98% confidence intervals for all outcomes
will be presented. Results will be declared significantly
"non-inferior" (primary outcome only) if the lower 98%
confidence interval for the imiquimod effect relative to
surgery is greater than the non-inferiority margin (0.87).
Greater confidence will be placed on the results (primary
outcome only) if the conclusions from the intention to
treat (ITT) and per protocol (PP) analysis are consistent.
Data analysis will remain blinded until all data analysis
has been performed and has been checked and approved
by the Data Monitoring Committee.
Primary outcome measure
The number and percentage of participants successfully
treated at 3 years in each treatment group, the absolute
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sponding 98% confidence interval for the absolute differ-
ence in percentages will be reported. The relative risk will
be used to indicate the risk of being treated successfully
in the imiquimod group relative to the surgery group.
Poisson regression with a robust error variance will be
used to estimate treatment effect, with centre and BCC
type (fixed effects) included as covariates. This approach
has been shown to be a reliable method to use for esti-
mating adjusted relative risks for prospective studies with
binary outcome variables [16].
Two separate analyses will be undertaken:
i) Adjusting for centre and tumour type
ii) Adjusting for centre, tumour type, tumour size,
tumour site and immunosuppression.
Secondary outcome measures
Clinical success at 1, 2 and 5 years will be analysed and
presented in the same way as for the primary outcome
variable.
Time to first recurrence (five categories): Compari-
son of treatment groups will use ordinal regression analy-
sis, adjusting for centre and BCC type (fixed effects). The
number and percentage of participants in each of the 5
time of first recurrence categories will be reported by
treatment group. The odds ratio arising from the contin-
uation ratio model and the corresponding 98% confi-
dence interval will be reported.
Cosmetic appearance of lesion site at 6 months and at
3 years as rated by the participant and by an independent
dermatologist. The analysis of primary interest will be the
participants rating at 6 months, focusing on head and
neck, and then on all sites. The analysis of the dermatolo-
gist's ratings will be based on lesions at all sites. For each
of the cosmetic appearance outcome measures, the num-
ber and percentage of participants with a lesion of excel-
lent or good appearance in each treatment group, the
absolute difference in percentages between groups and
the corresponding 98% confidence interval for the abso-
lute difference in percentages will be reported. The rela-
tive risk of having a lesion of excellent or good
appearance in the imiquimod group relative to the sur-
gery group and the corresponding two-sided 98% confi-
dence interval will be presented. The inclusion of baseline
variables in the model will be explored.
Level of pain: for each of the treatment period and the
16 week follow-up period, the number and percentage of
participants who experience the following levels of pain
(moderate or more severe, mild-moderate or less severe
pain, no pain) will be reported by treatment group. The
median number of days of moderate or more severe pain
will also be reported.
Cost effectiveness for the different treatment modali-
ties will be explored.
Treatment compliance in the imiquimod group will be
reported. The amount of imiquimod cream used will be
estimated from the daily diary (number of days of expo-
sure). Insufficient exposure to imiquimod cream will also
be reported (<4 weeks treatment for superficial BCCs; <8
weeks treatment for nodular BCCs), also the number
unable to complete the full course as a result of an
adverse event. In the surgery group treatment compliance
will be the receipt of excisional surgery.
Analysis of safety and tolerability
Participants will be analysed according to the treatment
they received, using descriptive statistics.
Full details of the analysis are given in a separate statis-
tical analysis plan.
Discussion
i) For large (greater than 4 cm diameter) superficial
BCCs, an efficacy of around 90% might make imiquimod
the treatment of choice because of better cosmetic results
despite being slightly inferior to excisional surgery
ii) For smaller superficial BCCs, an efficacy of around
90% could still make it a more attractive option to non-
surgical treatments with similar efficacy such as cryo-
therapy or curettage because it can be used at home
iii) Efficacy rates of as low as 70% for nodular BCC at
low-risk sites could still be useful and cost-effective for
dealing with the bulk of BCCs. These are non life-threat-
ening lesions which can be dealt with surgically if recur-
rences occur. In other words, a "treat with the cream first
and see what's left policy" might become a viable and
more cost effective future treatment option.
This summary paper is based on version 9 of the study
protocol, dated 27/07/06, and the analysis plan as at
March 2010. A copy of the full protocol and analysis plan
are available on request.
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